Molbio Diagnostics Ltd. Share Price

Important market news today!!

Important market news today - 🔥 Short-Term Stock Picks Anand Rathi recommends Aarti Industries, Bata India, and BDL for 1-2 week gains. - 📉 Market Outlook Caution Nifty 50 and Sensex expected to open lower amid geopolitical tensions and weak global cues. - ⛽ Oil Price Stability Brent crude holds near $88 amid stalled US-Iran talks; impacts energy sector sentiment. - 🚀 IPO Activity Surge Tempsens Instruments, Dhoot Transmission, and Molbio Diagnostics to list soon, signaling strong market IPO interest. - 💹 Paytm Rally & Mutual Fund Flows Paytm shares up 11%, boosted by positive targets; mutual fund equity AUM jumps ₹9.5 lakh crore.

IPO Market

The IPO market is set for a busy week ahead, with Dhoot Transmission and Molbio Diagnostics scheduled to list on Monday, 17 August, while Behari Lal Engineering and Shiprocket are set for their IPO allotment on the same day. Meanwhile, the Milky Mist Dairy Food IPO allotment was finalised on Friday, 14 August, with refunds and share credits scheduled to follow on Monday. The issues witnessed strong investor demand during the bidding period, with Dhoot Transmission receiving 74.21 times subscription, Behari Lal Engineering 108.44 times, Milky Mist Dairy Food 56.12 times, Shiprocket 99.38 times, and Molbio Diagnostics 70.26 times subscription on their respective final days.

Molbio Diagnostics IPO

Does stock fall in these catagories?: 1. Strong Recurring Revenue Model: The business operates like a printer-ink model; once the "TrueNat" machines are sold to government agencies, the company generates consistent, long-term revenue through the sale of proprietary test kits. 2. Industry Tailwinds WHO Approval: Being WHO-certified for TB diagnostics provides significant competitive moat and credibility, positioning the company as a leader in infectious disease testing. 3. High Growth Potential: The company has demonstrated strong revenue growth and is continuously investing in R&D and intellectual property patents to stay ahead of market shifts. 4. Stable Financial Foundation: The company maintains a healthy debt-to-equity ratio and positive cash flow, with significant manufacturing capacity still underutilized, allowing for future scale without massive immediate capex. Key Risks Discussed: Promoter/Investor Cashing Out: A large portion of the IPO proceeds ₹740 crore is an Offer for Sale OFS, meaning the money goes to existing shareholders rather than the company’s growth. Concentration Risk: Roughly 90% of revenue is derived from the Indian market and primarily from government contracts, creating high dependency on policy and state budgets. Commission Spikes: There has been a massive increase in commission expenses from ₹64 Cr to ₹170 Cr, which has hampered net profit margins despite revenue growth. Valuation Concerns: The IPO is priced at a premium 57x P/E, which is on par with, or higher than, established peers, leaving little "safety margin" for investors. Capacity vs. Sales Disconnect: Despite having high manufacturing capacity, sales outside India have seen a decline, raising questions about organic demand growth.

Molbio Diagnostics Files for ₹12,000+ Crore IPO.

Goa-based Molbio Diagnostics, backed by Temasek and Motilal Oswal PE, has filed papers for an IPO valued at over ₹12,490 crore. The issue will include a ₹200 crore fresh issue and a large offer-for-sale (OFS) of up to 1.25 crore shares by promoters and investors. Key points: • Fresh issue: ₹200 crore, funds to be used for R&D infrastructure, new equipment at Goa & Vizag units, and general corporate needs. • OFS: Promoters and investors (including Temasek and Motilal Oswal PE) will sell a major stake. • Valuation: Based on recent adjusted issue price of ₹1,090/share, the company is valued at ₹12,490.8 crore. • Business: Known for its Truenat platform, a rapid molecular PCR test used for 30 diseases, including TB. It’s one of only two such global platforms and the only one from India—giving it strong market entry barriers. • Financials: FY25 profit surged 66% to ₹138.6 crore, while revenue rose 22% to ₹1,020.4 crore. Why it stands out: • Operates in a niche, oligopolistic diagnostics space with very high entry barriers. • Strong backing from global and domestic investors. • IPO structure shows more focus on existing shareholders exiting (OFS-heavy), while fresh issue proceeds are mainly for R&D and capacity expansion. Summary: Molbio Diagnostics is bringing a large, OFS-driven IPO at a premium valuation, built on its strong Truenat platform and growing demand for rapid molecular testing. With global-standard tech and healthy financials, it positions itself as a rare high-quality diagnostics play on Dalal Street.